Cyclosporine, prednisone, and high-dose immunoglobulin treatment of angioimmunoblastic T-cell lymphoma refractory to prior CHOP or CHOP-like regimen
Authors:
Open Access
- 5 October 2011
- journal article
- Published by Editorial Office of Chinese Journal of Cancer in Chinese Journal of Cancer
- Vol. 30 (10) , 731-738
Abstract
Angioimmunoblastic T-cell lymphoma (AITL) is a rare, distinct subtype of peripheral T-cell lymphoma, possessing an aggressive course and poor prognosis with no standard therapy. Twelve patients who have failed at least two initial CHOP or CHOP-like regimens were enrolled in this study and treated with individualized cyclosporine (CsA), prednisone (PDN), and monthly, high-dose intravenous immunoglobulin (HDIVIG). The dose of CsA was adjusted individually based on the blood trough concentration of CsA and renal function. All patients were examined for response, toxicity and survival. The most significant toxicities (≥ grade 2) were infection (16.7%), renal insufficiency (8.3%), hypertension (8.3%), diabetes (8.3%) and insomnia (16.7%). Discontinuation of treatment occurred in one patient (8.3%) due to grade 3 renal toxicity and subsequent grade 4 pulmonary infection. Treatment-related death was not observed. The overall response rate was 75.0% (complete response, 33.3%; partial response, 41.7%). With a median follow-up of 25.5 months, the median duration of response was 20 months (range, 12 to 49 months) and the median progression-free survival (PFS) was 25.5 months (range, 10 to 56 months). The 2-year PFS rate was 81.5%. Our findings indicate the combination of CsA, PDN and HDIVIG is an effective salvage regimen for refractory or relapsed AITL with predictable and manageable toxicity.Keywords
This publication has 24 references indexed in Scilit:
- Angioimmunoblastic-Like T-Cell Non Hodgkin's Lymphoma: Outcome After Chemotherapy in 33 Patients and Review of the LiteratureLeukemia & Lymphoma, 1999
- Treatment of angioimmunoblastic T-cell lymphoma with cyclosporineAnnals of Oncology, 1997
- Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: Prognostic impact of clinical observations and laboratory findings at presentationAnnals of Oncology, 1995
- Angioimmunoblastic lymphadenopathy with dysproteinemia.1993
- Treatment of Angioimmunoblastic Lymphadenopathy (AILD)-Type T-Cell Lymphoma Using Prednisone with or without the COPBLAM/IMVP-16 RegimenAnnals of Internal Medicine, 1992
- Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with cyclosporin ACancer, 1992
- Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma.1992
- Intravenous Immunoglobulin for the Prevention of Infection in Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 1988
- Angioimmunoblastic lymphadenopathy long-term follow-up studyCancer, 1983
- Therapeutic effect of vincristine, adriamycin and prednisolone (VAP) in angioimmunoblastic lymphadenopathy (AIL)Cancer Chemotherapy and Pharmacology, 1983